Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease

PLoS Genet. 2014 May 8;10(5):e1004302. doi: 10.1371/journal.pgen.1004302. eCollection 2014 May.

Abstract

Alpha-synuclein (aSyn) is the main component of proteinaceous inclusions known as Lewy bodies (LBs), the typical pathological hallmark of Parkinson's disease (PD) and other synucleinopathies. Although aSyn is phosphorylated at low levels under physiological conditions, it is estimated that ∼ 90% of aSyn in LBs is phosphorylated at S129 (pS129). Nevertheless, the significance of pS129 in the biology of aSyn and in PD pathogenesis is still controversial. Here, we harnessed the power of budding yeast in order to assess the implications of phosphorylation on aSyn cytotoxicity, aggregation and sub-cellular distribution. We found that aSyn is phosphorylated on S129 by endogenous kinases. Interestingly, phosphorylation reduced aSyn toxicity and the percentage of cells with cytosolic inclusions, in comparison to cells expressing mutant forms of aSyn (S129A or S129G) that mimic the unphosphorylated form of aSyn. Using high-resolution 4D imaging and fluorescence recovery after photobleaching (FRAP) in live cells, we compared the dynamics of WT and S129A mutant aSyn. While WT aSyn inclusions were very homogeneous, inclusions formed by S129A aSyn were larger and showed FRAP heterogeneity. Upon blockade of aSyn expression, cells were able to clear the inclusions formed by WT aSyn. However, this process was much slower for the inclusions formed by S129A aSyn. Interestingly, whereas the accumulation of WT aSyn led to a marked induction of autophagy, cells expressing the S129A mutant failed to activate this protein quality control pathway. The finding that the phosphorylation state of aSyn on S129 can alter the ability of cells to clear aSyn inclusions provides important insight into the role that this posttranslational modification may have in the pathogenesis of PD and other synucleinopathies, opening novel avenues for investigating the molecular basis of these disorders and for the development of therapeutic strategies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy
  • Humans
  • Models, Biological*
  • Parkinson Disease / metabolism*
  • Phosphorylation
  • Saccharomyces cerevisiae / metabolism*
  • alpha-Synuclein / metabolism*

Substances

  • alpha-Synuclein

Grants and funding

This work was supported by Fundação para a Ciência e Tecnologia (http://www.fct.pt/) projects PTDC/SAU-NEU/105215/2008, PTDC/BIA-BCM/117975/2010, PEstOE/EQB/LA0004/2011 and PTDC/BIA-BCM/111617/2009, and fellowships SFRH/BPD/35767/2007 (ST), IMM/BTI/1-2012 (MMRP), SFRH/B I/5177/2011 (PA) and SFRH/BD/73429/2010 (DM), IMM/BTI/91-2012 (RRR) and SRFH/BPD/84618/2012 (CNS). AG and CNS are also supported by the European Commission project EUBerry FP7 KBBE-2010-4 26594. DW is supported by Wroclaw University statutory founds 1068/S/IBE/2013. DK and MW are supported by an Israel Science Foundation (http://www.isf.org.il/english/) grant (ISF 843/11), a grant from the GIF, the German-Israeli Foundation for Scientific Research and Development (http://www.gif.org.il)(2267-2166.9/2010), and a New Investigator in Alzheimer's Disease Grant from the American Federation for Aging Research (http://www.afar.org/). TFO was also supported by a Marie Curie International Reintegration Grant, an EMBO Installation Grant (http://ec.europa.eu/research/mariecurieactions/), and by the DFG Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB, http://www.uni-goettingen.de/en/45165.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.